We like Boston Scientific. Things were not good, particularly after Guidant take-over. Market makers do not like poor performance, and Boston did not return properly, after Guidant purchase. Boston still is far away from good performance: I suspect they overpaid for Guidant, and their CFO was unhappy with the amount of leverage. Clearly, they need to fix the balance sheet and said they would do so. But that will take some time.
But, current situation is better: The observational study published in the Feb. 1 issue of the American Journal of Cardiology, the company said, showed drug-eluted stents reduced the risk of myocardial infarction, or heart attack, and death by 23 percent and 32 percent, versus 3.7 percent and 4.7 percent in bare-metal stent patients.
No comments:
Post a Comment